Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)

NCT04809220 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04809220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04809220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
April 13, 2021
Completion date
April 26, 2023
Enrollment
591 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, diabetes mellitus, type 2, endocrine system diseases, glucose metabolism disorders, hypoglycemic agents, metabolic disease, type 2 diabetes mellitus (t2dm)